Amgen (AMGN) Claims Osteoporosis Break-Through
May 20, 2008 · Filed Under General
Amgen (AMGN) claims that it has developed a new and better drug treatment called denosumab for osteoporosis. The current drug of choice is Fosamax from Merck (MRK).
According to the AP “The one-year, Phase III clinical trial showed post-menopausal women gained more bone mass after transition to denosumab.”
A generic version of Fosamax is marketed by Teva (TEVA).
The news can’t be viewed as good for Merck
Douglas A. McIntyre